WARNING: The Thumbs up, thumbs down commentaries are freewheeling, sometimes contentious, always interesting discussions about the latest clinical trials affecting cardiologists.These discussions may ...
Pfizer’s sickle cell disease (SCD) drug has flunked a key phase 3 test, the latest blow to the pharma’s $5.4 billion acquisition of Global Blood Therapeutics. Pfizer acquired the P-selectin inhibitor, ...
81.7% of patients were on an SGLT2 inhibitor 74.7% of patients were on an ARNI 95.1% of patients were on a beta-blocker 83.1% of patients were on an MRA Despite high use of GDMT, the rate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback